A method of treating a diabetic patient comprising:nmeasuring a triglyceride level and HbA1c level in said diabetic patient;selecting said patient for treatment according to said triglyceride level being below a threshold, and HbA1c level being above a threshold; andapplying said treatment to said selected patient, said treatment comprising at least one of intra-abdominal and gastric electrical stimulation.
›2.↳ 1A method according to claim 1, wherein said applying comprises applying said treatment to reduce said HbA1c level by at least 1.0% after 3 months of s…d2
A method according to claim 1, wherein said applying comprises applying said treatment to reduce said HbA1c level by at least 1.0% after 3 months of said treatment.
›3.↳ 1A method according to claim 1, wherein said diabetic patient is a type 2 diabetic patient.d2
A method according to claim 1, wherein said diabetic patient is a type 2 diabetic patient.
›4.↳ 1A method according to claim 1, wherein said triglyceride threshold comprises a triglyceride level<=150 mg/dl.d2
A method according to claim 1, wherein said triglyceride threshold comprises a triglyceride level<=150 mg/dl.
›5.↳ 1A method according to claim 1, wherein said triglyceride threshold comprises a triglyceride level<=120 mg/dl.d2
A method according to claim 1, wherein said triglyceride threshold comprises a triglyceride level<=120 mg/dl.
›6.↳ 1A method according to claim 1, wherein said triglyceride threshold comprises a triglyceride level<=180 mg/dl.d2
A method according to claim 1, wherein said triglyceride threshold comprises a triglyceride level<=180 mg/dl.
›7.↳ 1A method according to claim 1, wherein said applying comprises applying said diabetes treatment according to a function of triglyceride levels and exp…d2
A method according to claim 1, wherein said applying comprises applying said diabetes treatment according to a function of triglyceride levels and expected effects of treatment.
›8.↳ 1A method according to claim 1, wherein said triglyceride level comprises a fasting plasma triglyceride level.d2
A method according to claim 1, wherein said triglyceride level comprises a fasting plasma triglyceride level.
›9.↳ 1A method according to claim 1, further comprising:nreducing said triglyceride level in said patient during at least one of before and during said trea…d2+4
A method according to claim 1, further comprising:nreducing said triglyceride level in said patient during at least one of before and during said treatment.
›10.↳ 9A method according to claim 9, wherein said reducing comprises administering at least one drug.d3+1
A method according to claim 9, wherein said reducing comprises administering at least one drug.
›11.↳ 10A method according to claim 10, wherein said at least one drug comprises selecting from the group consisting of: statin, fibrate, niacin.d4
A method according to claim 10, wherein said at least one drug comprises selecting from the group consisting of: statin, fibrate, niacin.
›12.↳ 9A method according to claim 9, wherein said reducing comprises at least one dietary change.d3+1
A method according to claim 9, wherein said reducing comprises at least one dietary change.
›13.↳ 12A method according to claim 12, wherein said at least one dietary change comprises selecting from the group consisting of: reducing fat, reducing carb…d4
A method according to claim 12, wherein said at least one dietary change comprises selecting from the group consisting of: reducing fat, reducing carbohydrates, increasing omega-3 fatty acids, reducing alcohol.
›14.↳ 1A method according to claim 1, further comprising:nmonitoring changes in said triglyceride level during at least one of said treatment and during said…d2
A method according to claim 1, further comprising:nmonitoring changes in said triglyceride level during at least one of said treatment and during said treatment; andat least one of adjusting said treatment parameters according to said changes and adjusting said triglyceride levels.
›15.↳ 1A method according to claim 1, further comprising:nmeasuring a glycemic level in said diabetic patient;selecting said patient for treatment according …d2+1
A method according to claim 1, further comprising:nmeasuring a glycemic level in said diabetic patient;selecting said patient for treatment according to said glycemic level being above a glycemic threshold;applying said treatment to said selected patient to reduce said glycemic level.
›16.↳ 15A method according to claim 15, wherein said glycemic level comprises an HbA1c level>=8%.d3
A method according to claim 15, wherein said glycemic level comprises an HbA1c level>=8%.
›17.↳ 1A method according to claim 1, further comprising selecting said patient for treatment according to said patient taking at least one oral diabetes med…d2+1
A method according to claim 1, further comprising selecting said patient for treatment according to said patient taking at least one oral diabetes medication.
›18.↳ 17A method according to claim 17, wherein said at least one oral diabetes medication comprises one or more of; insulin, GLP-1 receptor agonist therapy, …d3
A method according to claim 17, wherein said at least one oral diabetes medication comprises one or more of; insulin, GLP-1 receptor agonist therapy, oral antidiabetic agent.
›19.↳ 1A method according to claim 1, further comprising:nmeasuring a weight of said diabetic patient;selecting said patient for treatment according to said …d2+2
A method according to claim 1, further comprising:nmeasuring a weight of said diabetic patient;selecting said patient for treatment according to said weight level being above a weight threshold; andapplying said treatment to said selected patient to reduce said weight.
›20.↳ 19A method according to claim 19, wherein said weight threshold comprises a BMI>=25.0 kg/m2.d3+1
A method according to claim 19, wherein said weight threshold comprises a BMI>=25.0 kg/m2.
›21.↳ 20A method according to claim 20, wherein said reduce weight comprises reduce weight by at least 5 kg after 6 months of said treatment.d4
A method according to claim 20, wherein said reduce weight comprises reduce weight by at least 5 kg after 6 months of said treatment.
›22.↳ 1A method according to claim 1, further comprising:ncalculating a HOMA-IR of said diabetic patient to establish a baseline;applying said treatment to s…d2+1
A method according to claim 1, further comprising:ncalculating a HOMA-IR of said diabetic patient to establish a baseline;applying said treatment to said patient to reduce said HOMA-IR relative to said baseline.
›23.↳ 22A method according to claim 22, wherein applying comprises applying said treatment to reduce said HOMA-IR by at least about 2.0 points after about 6 m…d3
A method according to claim 22, wherein applying comprises applying said treatment to reduce said HOMA-IR by at least about 2.0 points after about 6 months of said treatment.
›24.↳ 1A method according to claim 1, wherein said applying comprises applying to extend life of beta cells.d2
A method according to claim 1, wherein said applying comprises applying to extend life of beta cells.
›25.↳ 1A method according to claim 1, further comprising:nmeasuring a blood pressure of said diabetic patient;selecting said patient for treatment according …d2+1
A method according to claim 1, further comprising:nmeasuring a blood pressure of said diabetic patient;selecting said patient for treatment according to said blood pressure being above at least one of a systolic and a diastolic threshold; andapplying said treatment to said selected patient to reduce said blood pressure.
›26.↳ 25A method according to claim 25, wherein said systolic threshold comprises 130 mmHg and said diastolic threshold comprises 80 mmHg.d3
A method according to claim 25, wherein said systolic threshold comprises 130 mmHg and said diastolic threshold comprises 80 mmHg.
›27.↳ 1A method according to claim 1, further comprising:nmeasuring an insulin/glucose ratio of said diabetic patient to establish a baseline;applying said t…d2
A method according to claim 1, further comprising:nmeasuring an insulin/glucose ratio of said diabetic patient to establish a baseline;applying said treatment to said selected patient to increase said insulin/glucose ratio relative to said baseline.
›28.↳ 1A method according to claim 1, wherein said applying comprises applying said treatment to reduce at least one of HbA1c level, HOMA-IR level, blood pre…d2
A method according to claim 1, wherein said applying comprises applying said treatment to reduce at least one of HbA1c level, HOMA-IR level, blood pressure, and patient's weight.
›29.↳ 1A method according to claim 1, wherein said applying comprises applying said treatment to increase an insulin to glucose ratio.d2
A method according to claim 1, wherein said applying comprises applying said treatment to increase an insulin to glucose ratio.